Supernus Pharmaceuticals
SUPN
247 hedge funds and large institutions have $1.44B invested in Supernus Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 40 funds opening new positions, 91 increasing their positions, 89 reducing their positions, and 19 closing their positions.
111% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 19
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
26% more capital invested
Capital invested by funds: $1.14B → $1.44B (+$299M)
11% more call options, than puts
Call options by funds: $10.5M | Put options by funds: $9.47M
6% more funds holding
Funds holding: 234 → 247 (+13)
2% more repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 89
0.37% more ownership
Funds ownership: 91.57% → 91.94% (+0.37%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$179M |
| 2 |
PC
Polar Capital
London,
United Kingdom
|
+$9.92M |
| 3 |
Millennium Management
New York
|
+$7.65M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$7.27M |
| 5 |
Axa
Paris,
France
|
+$5.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$14M |
| 2 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
-$13.6M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$7.61M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$7.5M |
| 5 |
Morgan Stanley
New York
|
-$4.3M |
SUPN Hedge Fund Activity: Q1 2017 in Review
247 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q1 2017, worth a combined $1.44B — up 26% from $1.14B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new SUPN positions and 19 closed out — a net gain of 21 holders — while 91 added to existing stakes and 89 trimmed.
The largest buyer was BlackRock, adding an estimated $179M. The largest seller was Granahan Investment Management, cutting an estimated $14M.
- 247 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q1 2017, up from 234 in Q4 2016.
- Funds reported $1.44B of Supernus Pharmaceuticals stock for Q1 2017, up 26% quarter-over-quarter.
- 40 funds opened new Supernus Pharmaceuticals positions in Q1 2017 and 19 closed out, a net change of +21 holders.
- The largest Supernus Pharmaceuticals buyer in Q1 2017 was BlackRock, an estimated $179M added.
- The largest Supernus Pharmaceuticals seller in Q1 2017 was Granahan Investment Management, an estimated $14M sold.
Based on aggregated 13F filings for Q1 2017.